When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis

Of mice, flies - and men? Comparing fungal infection models for large-scale screening efforts

(2015) S. Brunke et al.   Disease Models & Mechanisms

Decline In Economic Returns From New Drugs Raises Questions About Sustaining Innovations

(2015) Ernst R. Berndt et al.   HEALTH AFFAIRS

Progression-seeking bias and rational optimism in research and development

(2015) Dennis W. Lendrem et al.   NATURE REVIEWS DRUG DISCOVERY

Risk of Bias in Reports of In Vivo Research: A Focus for Improvement

(2015) Malcolm R. Macleod et al.   PLOS BIOLOGY

Chasing Mendel: five questions for personalized medicine

(2014) Michael J. Joyner et al.   JOURNAL OF PHYSIOLOGY-LONDON

Policy: NIH plans to enhance reproducibility

(2014) Francis S. Collins et al.   NATURE

Preclinical research: Make mouse studies work

(2014) Steve Perrin   NATURE

Clinical development success rates for investigational drugs

(2014) Michael Hay et al.   NATURE BIOTECHNOLOGY

The role of ligand efficiency metrics in drug discovery

(2014) Andrew L. Hopkins et al.   NATURE REVIEWS DRUG DISCOVERY

Rescuing US biomedical research from its systemic flaws

(2014) B. Alberts et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An investigation of the false discovery rate and the misinterpretation of p-values

(2014) D. Colquhoun   Royal Society Open Science

Models and Standards of Proof in Cross-Disciplinary Science: The Case of Arsenic DNA

(2013) Steven A. Benner et al.   ASTROBIOLOGY

Inconsistency in large pharmacogenomic studies

(2013) Benjamin Haibe-Kains et al.   NATURE

Chemical predictive modelling to improve compound quality

(2013) John G. Cumming et al.   NATURE REVIEWS DRUG DISCOVERY

Platforms for antibiotic discovery

(2013) Kim Lewis   NATURE REVIEWS DRUG DISCOVERY

Power failure: why small sample size undermines the reliability of neuroscience

(2013) Katherine S. Button et al.   NATURE REVIEWS NEUROSCIENCE

Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays

(2013) Patricia Dranchak et al.   PLoS One

Threats to Validity in the Design and Conduct of Preclinical Efficacy Studies: A Systematic Review of Guidelines for In Vivo Animal Experiments

(2013) Valerie C. Henderson et al.   PLOS MEDICINE

Rethinking Molecular Similarity: Comparing Compounds on the Basis of Biological Activity

(2012) Paula M. Petrone et al.   ACS Chemical Biology

Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift

(2012) Frank Sams-Dodd   DRUG DISCOVERY TODAY

A call for transparent reporting to optimize the predictive value of preclinical research

(2012) Story C. Landis et al.   NATURE

Raise standards for preclinical cancer research

(2012) C. Glenn Begley et al.   NATURE

Quantifying the chemical beauty of drugs

(2012) G. Richard Bickerton et al.   Nature Chemistry

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Comparison of Family History and SNPs for Predicting Risk of Complex Disease

(2012) Chuong B. Do et al.   PLoS Genetics

Challenges of Antibacterial Discovery

(2011) L. L. Silver   CLINICAL MICROBIOLOGY REVIEWS

How were new medicines discovered?

(2011) David C. Swinney et al.   NATURE REVIEWS DRUG DISCOVERY

Trends in the exploitation of novel drug targets

(2011) Mathias Rask-Andersen et al.   NATURE REVIEWS DRUG DISCOVERY

The productivity crisis in pharmaceutical R&D

(2011) Fabio Pammolli et al.   NATURE REVIEWS DRUG DISCOVERY

Believe it or not: how much can we rely on published data on potential drug targets?

(2011) Florian Prinz et al.   NATURE REVIEWS DRUG DISCOVERY

Improving Validation Practices in "Omics" Research

(2011) J. P. A. Ioannidis et al.   SCIENCE

Breaking Free of Sample Size Dogma to Perform Innovative Translational Research

(2011) P. Bacchetti et al.   Science Translational Medicine

Negative results are disappearing from most disciplines and countries

(2011) Daniele Fanelli   SCIENTOMETRICS

Current sample size conventions: Flaws, harms, and alternatives

(2010) Peter Bacchetti   BMC Medicine

Analysis of Food and Drug Administration-Approved Anticancer Agents in the NCI60 Panel of Human Tumor Cell Lines

(2010) S. L. Holbeck et al.   MOLECULAR CANCER THERAPEUTICS

Hit finding: towards ‘smarter’ approaches

(2009) Thierry Langer et al.   CURRENT OPINION IN PHARMACOLOGY

Common Genetic Variation and Human Traits

(2009) David B. Goldstein   NEW ENGLAND JOURNAL OF MEDICINE

Simple, Defensible Sample Sizes Based on Cost Efficiency

(2008) Peter Bacchetti et al.   BIOMETRICS

Why Current Publication Practices May Distort Science

(2008) Neal S Young et al.   PLOS MEDICINE